Overview

Placebo Versus SBR759 in Lowering Phosphate in Dialysis Patients

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will compare placebo to 4 different doses of SBR759 to assess the phosphate lowering efficacy in dialysis patients.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis
Treatments:
Ferric Compounds